NantOmics
9920 Jefferson Blvd, Culver City, CA, 90232, United States
Overview
NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Alternative Medicine
- Biotechnology
- Cloud Data Services
- Genetics
- Health Care
- Life Science
Investment portfolio
- Genos
Led · Equity · Nov 2016
Genos uses next-generation sequencing to profile users' exomes, providing richer genetic detail than SNP-based tests. The company plans to sequence whole genomes in the near future but is starting with exome sequencing to focus on protein-coding variants important to rare-disease discovery. Genos aims to create a crowdsourced genetic map by incentivizing individuals—paying for their information each time it is used rather than relying on blanket consent. The startup is gearing up for an official launch in a few months and says it will disclose participant payment amounts closer to that date. Genos recently closed a $6 million strategic investment from cancer discovery platform NantOmics. Its advisory board includes genomics leader George Church, Nobel laureate economist Alvin E. Roth, and former Uber exec Mina Radhakrishnan.
Team
No current team members are available.